Roivant Sciences (NASDAQ:ROIV) Maintains "Buy" Rating Amid Promising Developments

Font: Financial Modeling Prep  • Feb 07, 2026

• Cowen & Co. maintains a "Buy" rating for Roivant Sciences, with a significant price target increase from $28 to $38, reflecting confidence in the company's future.
• Roivant's stock has seen a notable increase of 22.14%, reaching a new 52-week high of $25.92, driven by promising data from Brepocitinib.
• The company's market capitalization stands at approximately $17.96 billion, indicating a strong presence in the biotech industry and active investor engagement.

Roivant Sciences (NASDAQ:ROIV) is a biopharmaceutical company focused on developing transformative medicines. It has gained attention for its innovative approach to drug development, often partnering with other companies to bring new treatments to market. Roivant's competitors include other biotech firms that are also working on cutting-edge therapies.

On February 6, 2026, Cowen & Co. maintained its "Buy" rating for Roivant Sciences, with the stock priced at $25.82. This endorsement reflects confidence in Roivant's potential, especially with the recent release of Brepocitinib's promising data. The stock has seen a notable increase of 22.14%, or $4.68, indicating strong market interest.

TD Cowen raised Roivant's price target from $28 to $38, as highlighted by TheFly. This adjustment aligns with the company's recent achievements, such as Brepocitinib's success. The stock has reached a new 52-week high of $25.92, showcasing investor optimism about Roivant's future prospects.

Roivant's market capitalization stands at approximately $17.96 billion, reflecting its significant presence in the biotech industry. The stock's trading volume is 23.84 million shares, indicating active investor engagement. The stock's fluctuation between $23.97 and $25.95 today further underscores its dynamic market performance.

With a 52-week low of $8.73, Roivant's current price of $25.82 highlights its impressive growth trajectory. The company's advancements, particularly with Brepocitinib, position it as a potential successor to Telavant, suggesting a promising future in the biopharmaceutical sector.